Profile of pathogenic proteins in total circulating extracellular vesicles in mild cognitive impairment and during the progression of Alzheimer's disease.
Aged
Aged, 80 and over
Alzheimer Disease
/ diagnosis
Amyloid beta-Peptides
/ metabolism
Biomarkers
/ metabolism
Brain
/ metabolism
Cognitive Dysfunction
/ diagnosis
Diagnosis, Differential
Disease Progression
Extracellular Vesicles
/ metabolism
Female
Humans
Male
Phosphorylation
tau Proteins
/ metabolism
APP
Amyloid
Biomarkers
Exosomes
MMSE
MoCA
Tau
Journal
Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
07
06
2019
revised:
20
10
2019
accepted:
21
10
2019
pubmed:
31
12
2019
medline:
8
9
2020
entrez:
30
12
2019
Statut:
ppublish
Résumé
Accumulating evidence suggests that the propagation of hyperphosphorylation of tau protein and the amyloid-β peptide can be mediated by extracellular vesicles (EVs) and be associated with the onset and the progression of Alzheimer's disease (AD). As EVs may transfer between the brain and the blood, we have thus hypothesized that the total plasma EVs (pEVs) may contain potential markers to predict the mild cognitive impairment (MCI) and AD progression. We have thus quantified AD-related proteins in isolated pEVs from controls, MCI and AD subjects. In pEVs, we observed early changes of total tau (tTau), amyloid precursor protein levels, and phospho-tau (pTau)-T181/tTau ratio from MCI subjects and late increases of Aβ42 and pTau-T181 levels from patients with moderate AD. Interestingly, abnormal amyloid precursor protein levels and pTau-T181/tTau ratio in pEVs demonstrated a high accuracy to define MCI and AD staging. Although larger samples sizes will be needed to generate well-powered investigations, these preliminary results highlighted the potential of AD-related proteins enriched in pEVs as a sensitive tool for differentiating patients with MCI to patients with AD and monitoring AD progression.
Identifiants
pubmed: 31883770
pii: S0197-4580(19)30373-2
doi: 10.1016/j.neurobiolaging.2019.10.010
pii:
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102-111Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.